Register for this FREE Solution Provider Webinar: Biomarker Strategies for More Efficient Early-Phase Drug Development in Alzheimer’s Disease

Register for this FREE Solution Provider Webinar
Biomarker Strategies for More Efficient Early-Phase Drug Development in Alzheimer’s Disease
May 21 | 11:00 AM-12:00 PM ET | Online

Brought to you by DIA in cooperation with ICON Plc

The development of validated biomarkers for Alzheimer's disease is essential to improve early diagnosis and accelerate the development of new therapies. It will aid in understanding the mechanism of action of a drug, identifying efficacy or toxicity signals at an early stage of development, and in identifying patients likely to respond to treatment. Biochemical and neuroimaging markers can facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment (MCI), and monitor efficacies of disease-modifying therapies.

In this FREE webinar, you will learn:
· Drug Development in Alzheimer's Disease – Using Data Analytics to Turn Challenges into
Opportunities
· The Use of Molecular Markers in CSF and Plasma in Alzheimer Disease – The Laboratory Perspective
· Advances in Imaging Biomarkers in AD Drug Development to Enable Accelerated Approval –
Fluorodeoxyglucose PET and Functional MRI
· Recent FDA Draft Guidance on Developing Drugs for Alzheimer’s Disease – Key Considerations
Presenters:
· John Allinson, VP Biomarker Lab Services, ICON Development Solutions, UK
· Niels Prins, MD, PhD, MSc, CEO, Alzheimer Research Center (ARC), Netherlands
· Michael N Liebman, PhD, President/Managing Director, IPQ Analytics, United States
· Klaudius Siegfried, PhD, VP & Global Leader Therapeutic Area CNS (Central Nervous System), ICON
Clinical Research, Germany
Overview | Register Online for FREE!


Sign up for DIA's Global SmartBrief eNews for the latest in drug development innovations worldwide.

First of DIA's Solution Provider Webinars - Oncology Clinical Trial Endpoints - March 11

From DIA

New at DIA: Solution Provider Webinars DIA's Solution Provider Webinars offer FREE access to cutting-edge information presented by some of the industry's leading experts, right from the comfort of your home or office. Our first Solution Provider Webinar will be brought to you by DIA in cooperation with ICON plc. Oncology Clinical Trial Endpoints: Keys to Maximizing Success in Your Development Programs March 11 | 11:00 AM-12:30 PM EST The high cost of drug development is partly due to the high rates of failure. Understanding why some trials of promising products do not succeed makes it more likely that your next trial will avoid the pitfalls. In this FREE webinar you will learn the strategies needed to improve your cancer development programs and discuss how the implementation of better trial design and medical imaging data provide early indicators on future drug success. Featured topics:      • Why are Oncology Clinical Trial Success Rates so Low?      • Challenges and Strategies to Improve Cancer Drug Development      • Medical Imaging in Oncology Trials: How do we get From Images to Endpoints?      • New Strategies for Improving Early Stage Cancer Drug Development Presenters: Samuel C. Blackman, MD, PhD Executive Director, Head of Translational Medicine, Seattle Genetics, Inc., United States James J. Conklin, MD, MS Senior Vice President, Medical and Scientific Affairs, ICON Medical Imaging, United States Jamal Gasmi, MD, PhD Vice President and Global Leader, Oncology and Hematology Drug Development, ICON Clinical Research, France Gregory V. Goldmacher, MD, PhD Director, Medical and Scientific Affairs, Head of Oncology Imaging, ICON Medical Imaging, United States Overview | Register FREE Online